A new version of the drug catalog is about to be released Children's drug research and development into the fast lane

Starting with Children's Day in June, the much-anticipated new version of the drug catalog is coming out, and "Child Drug Safety" is once again in the spotlight. According to the 2019 National Health Insurance Drug Catalog Adjustment Work Programme (Draft for Comments) released by the National Health Insurance Administration, a new version of the drug catalogue will be issued in June this year, with children's medications named as priority for transfer to medicines. Industry experts believe that this will promote children's drug research and development into a rapid development stage.The prospects for the children's drug market are promisingthe 2019 National Health Insurance Drug Catalog Adjustment Work Programme (Draft for Comments) shows that a new version of the drug catalog will be released in June this year, announcing the list of drugs to be negotiated. The transfer of medicines will give priority to the treatment of major diseases such as basic drugs, cancer and rare diseases, chronic diseases, children's medicines, emergency rescue drugs, etc.the person in charge of drug manufacturers frankly, China's market for children's special drugs are relatively scarce, for a long time are in the "three less" situation, that is, fewer manufacturers, fewer varieties, less suitable dosage form. More than 90% of the drugs do not have children's dosage forms, dosages, which will also lead to indiscriminate use of drugs, adverse reactions.in order to solve the problem of shortage of children's drugs, in recent years, the state has issued a number of policies to encourage the development and innovation of children's drugs, shorten the approval cycle of children's drug registration applications. The 2017 edition of the medical insurance catalogue added 91 new varieties of children's medicines, to a certain extent, alleviated the lack of drug types and dosage forms for children in China., the problem of pharmaceutical forms in children has improved considerably. 306 hospital paediatric director Zheng Cheng told reporters that particulate agents, punches, water agents and other suitable for children to take the dosage form ratio has been greatly increased, needles and tablets and other small specifications, suitable for different age groups of drugs have also increased significantly.the upcoming edition of the drug catalog will give priority to children's drug use into medicines, as a way to encourage pharmaceutical companies to promote research and development of children's medicine, care for children's drug market to grow. Industry experts believe that this will promote children's drug research and development into the fast lane, meaning that China's children's drug market prospects are promising. With the strengthening of national policy support and the impact of increased medical investment, the size of China's children's drug market is expected to maintain double-digit annual growth in the future.more pharmaceutical companies focus on children's drug research and development experts pointed out that from the entire pharmaceutical market, children's drug sales accounted for only 3% of China's pharmaceutical market. According to a survey from the National Chamber of Commerce and Industry, of the more than 6,000 pharmaceutical companies in China, only 10 specialize in the production of children's medicines, and only more than 30 enterprises specializing in the production of children's medicines., why are children's medicines a "cold" area that most businesses don't want to get involved in?Dongliang, regional general manager of China Resources 39 Beijing-Tianjin-Hebei, pointed out that the research and development of new drugs for children is more difficult and more expensive than ordinary new drugs, while the safety of children's medicinal supplements has higher requirements. From the time of development to market, the general new drugs about 10-12 years, children's new drugs as high as 14-16 years. In addition, clinical subjects of children's drug research and development are also more difficult to find. These factors have led pharmaceutical companies to be less motivated to develop drugs for children.
the background of the national policy, more and more enterprises have increased their investment in research and development of children's medicines. At present, China's research and development, the production of children's drugs of the main enterprises have sunflower medicine, China Resources 39, Johnson and Johnson, San jing pharmaceutical, the brand mainly has small sunflowers, 999 children cold, Merrill Lynch, small quick, Yukadan, good dolls, among which the treatment of diseases mainly children cold, indigestion, cough sputum and so on." children's drug production and marketing enterprises should develop special drugs for children, and continuously improve the quality standards of production, to ensure that children's drug use is safe and effective, to fulfill the social responsibility of pharmaceutical enterprises. Tang Dongliang, regional general manager of China Resources 39 Beijing-Tianjin-Hebei, said that China Resources 39 has been actively developing new pharmaceutical products for children in recent years, and has also conducted research on the use of children's products, while also conducting research on the production process and quality of products and setting standards to continuously improve product efficacy and safety.according to Sunflower Pharmaceuticals' 2018 annual report, the company's ibuprofen suspension has received clinical approval during the reporting period, and the supplementary study is now largely complete. According to the first batch of classic list published by the state, sunflower has chosen to carry out 7 research and development projects of classic famous party, are currently carrying out material benchmark research. In addition, for children's dispersal agents, oral fluids, granulant drugs to change taste, modified dosage forms and other items, is also in an orderly study., president of Sunflower Pharmaceuticals, said, "The real corporate strategy must be to solve social problems, children's medicine is the first strategy of sunflower pharmaceutical industry." It is not only our obligation, but also our business, to ensure the safety of Chinese children. " with the support of national policies and the follow-up of resources, the children's drug market will usher in development opportunities, there will be more enterprises to increase investment in children's medicine. Experts called for "child drug safety is a complex system engineering, requiring the participation of the government, scientific research, medical care, pharmaceutical companies, the public and many other forces to support." " (Beijing Evening News)